Search





Search





Markets
/
Stocks
/
nasdaq-edsa
/

Edesa Biotech Inc

EDSA

Add to Watchlist

16.300USD

-1.130-6.48%

Close 05/08, 16:00（ET）Quotes delayed by 15 min

144.84MMarket Cap

LossP/E TTM



Edesa Biotech Inc

16.300

-1.130-6.48%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Edesa Biotech Inc

Currency: USD Updated: 2026-05-08

Key Insights

Edesa Biotech Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 83 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Edesa Biotech Inc's Score

Industry at a Glance

Industry Ranking

83 / 384

Overall Ranking

211 / 4494

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Edesa Biotech Inc Highlights

StrengthsRisks

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.

Undervalued

The company’s latest PE is -15.32, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 4.36M shares, increasing 23.31% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 37.44K shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.000

Target Price

-36.89%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-08

The current financial score of Edesa Biotech Inc is 6.94, ranking 161 out of 384 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.94

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.66

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Edesa Biotech Inc's Company Valuation

Currency: USD Updated: 2026-05-08

The current valuation score of Edesa Biotech Inc is 6.60, ranking 240 out of 384 in the Biotechnology & Medical Research industry. Its current P/E ratio is -15.32, which is -99.19% below the recent high of -0.12 and -12.12% above the recent low of -17.17.

Score

Industry at a Glance

Previous score

6.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 83/384

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-08

The current earnings forecast score of Edesa Biotech Inc is 8.00, ranking 161 out of 384 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 19.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.000

Target Price

-36.89%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

553

Total

Median

Average

Company name

Ratings

Analysts

Edesa Biotech Inc

EDSA

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-08

The current price momentum score of Edesa Biotech Inc is 9.38, ranking 34 out of 384 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 22.73 and the support level at 7.47, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.58

Change

-0.2

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.983

Buy

RSI(14)

68.062

Neutral

STOCH(KDJ)(9,3,3)

66.396

Neutral

ATR(14)

2.557

High Vlolatility

CCI(14)

62.929

Neutral

Williams %R

29.364

Buy

TRIX(12,20)

5.562

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

16.057

Buy

MA10

15.748

Buy

MA20

11.025

Buy

MA50

7.914

Buy

MA100

4.618

Buy

MA200

3.413

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-08

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Velan Capital Investment Management LP

827.50K

+20.36%

Rubric Capital Management LP

687.50K

Stonepine Capital Management, LLC

687.50K

Nantahala Capital Management, LLC

625.00K

Point72 Asset Management, L.P.

Star Investors

600.00K

Nijhawan (Pardeep)

562.55K

+2.56%

Perceptive Advisors LLC

563.24K

Pardeep Nijhawan Medicine Professional Corporation

371.70K

+8.78%

DRW Securities, LLC

134.22K

Brooks (Michael J Ph.D.)

97.41K

+2.10%

Risk Assessment

Currency: USD Updated: 2026-05-08

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Edesa Biotech Inc is 2.19, ranking 236 out of 384 in the Biotechnology & Medical Research industry. The company's beta value is 1.27. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.